Impact BioMedical, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Impact BioMedical, INC. (IBO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $13.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- Impact BioMedical, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $8.00K.
- Impact BioMedical, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.00K.
- Impact BioMedical, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $13.00K, a 31.58% decline from fiscal 2024.
- Impact BioMedical, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $19.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $9.00K derived: sum of 2 quarters · filed 2026-03-11 | $13.00K 10-K · filed 2026-03-11 | |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $5.00K 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $19.00K 10-K · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |